Drugs / Naloxone
Naloxone
also known as
Naloxone hydrochloride · Naloxone = Narcan · Naloxone HCl · Narcan · 6β-Naltrexol · AIKO-150 · Anhydrous naloxone hydrochloride · Dbl naloxone · +38 more
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | REXTOVY | — | 2026-06-16 | fda.gov ↗ |
| Label expansion | US (FDA) | KLOXXADO | — | 2025-08-25 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | NARCAN | — | 1992-05-29 – 2023-03-29 | fda.gov ↗ |
| Approved | EU (EMA) | Suboxone | — | 2006-09-26 | europa.eu ↗ |
| Approved | US (FDA) | NARCAN | — | 1971-04-13 | fda.gov ↗ |
Trials 147 · started per year
today
US approved 1971
EU approved 2006
1
1
2
1
3
2
3
1
2
4
4
4
8
10
5
7
5
10
9
7
5
9
9
6
6
6
6
3
4
3
1
197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT04650841 | Sep 2026 → Mar 2027 expected | — | Trustees of Dartmouth College | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05490134 | Mar 2023 → Jan 2027 expected | pain agnosia | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 0 | NCT05099614 | Mar → Apr 2021 | acute opioid poisoning | University of Washington | Completed | No outcome recorded |
| Phase 0 | NCT04034004 | Jan 2021 → Dec 2022 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT04744883 | Aug 2020 → Nov 2024 overdue | chronic pain syndrome | Rush University Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03743805 | Jan 2019 → Jul 2021 | acute opioid poisoning, brain hypoxia - ischemia, cardiac arrest | Prisma Health-Midlands | Withdrawn | No outcome recorded |
| Phase 0 | NCT03766893 | Sep → Dec 2018 | opiate dependence | Lifespan | Completed | No outcome recorded |
| Phase 0 | NCT03096353 | Aug 2017 → Oct 2018 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 0 | NCT03419858 | Mar → Jun 2017 | — | University of California, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT01591629 | Nov 2011 → Jun 2012 | — | Yale University | Completed | No outcome recorded |
| Phase 132 trials | ||||||
| Phase 1 | NCT04975334 | Jun → Sep 2025 | hypogonadotropic hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT07180420 | Mar → Apr 2024 | — | STAT Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT06306391 | Mar → May 2024 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT05528848 | Sep 2022 → Sep 2027 expected | substance-related disorder | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05338632 | Jun 2022 → Aug 2026 overdue | respiratory underresponsiveness to hypoxia and hypercapnia, substance-related disorder | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04975347 | Jun 2022 → Aug 2025 | reproductive system disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05377255 | Mar → May 2022 | acute opioid poisoning | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 1 | NCT04764630 | Mar 2021 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT05264493 | Oct 2020 → Jan 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04454281 | Oct → Dec 2020 | dry eye syndrome, neuropathy, painful | Seema Capoor | Completed | No outcome recorded |
| Phase 1 | NCT04473950 | Jan 2020 → Oct 2022 | chronic pain syndrome, opiate dependence | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 1 | NCT03827642 | Apr → May 2018 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT03386591 | Jan → Feb 2018 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT03827629 | Aug 2017 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT02733822 | Jun 2016 → Jun 2017 | substance-related disorder | King's College London | Unknown | No outcome recorded |
| Phase 1 | NCT02598856 | Mar → Dec 2016 | — | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT03851731 | Oct → Nov 2015 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT02572089 | Oct 2014 → Jan 2015 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT02880475 | Jun 2014 → Jun 2015 | chronic pain syndrome | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01952782 | Apr 2014 → May 2016 | hypogonadotropic hypogonadism | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02158117 | Mar → Nov 2014 | — | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT01935206 | Jun → Nov 2013 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 1 | NCT02070718 | Jan → Jul 2013 | — | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT01396005 | Sep → Dec 2011 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01068847 | Feb 2010 → Oct 2012 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00829777 | Mar → Sep 2009 | opiate dependence | California Pacific Medical Center Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00750048 | Sep → Nov 2008 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00733720 | Aug → Dec 2008 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00733239 | Aug 2008 → Oct 2010 | opiate dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT00593463 | Sep 2006 → May 2010 | drug dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT01367561 | Oct 2002 → May 2003 | — | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00015288 | Nov 1996 → ? | heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03751111 | Feb → Mar 2019 | — | Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 1/2 | NCT02700048 | Jun 2016 → Jul 2021 | type 1 diabetes mellitus | University of Minnesota | Terminated | No outcome recorded |
| Phase 1/2 | NCT02307721 | Dec 2014 → Apr 2015 | — | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT04737603 | Jul 2025 | opiate dependence | University of California, Davis | Withdrawn | No outcome recorded |
| Phase 2 | NCT04480554 | Jan 2023 → Jun 2025 | HIV infectious disease, opiate dependence | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT05114460 | Nov 2021 → Oct 2024 | acute opioid poisoning | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03420313 | Mar 2018 → Jul 2021 | opiate dependence | University of Vermont | Unknown | No outcome recorded |
| Phase 2 | NCT02976337 | Oct 2017 → Nov 2023 | — | mads u werner | Completed | No outcome recorded |
| Phase 2 | NCT03149770 | Sep 2017 → May 2022 | type 1 diabetes mellitus | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02805972 | May 2017 → Jul 2018 | obesity disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02684669 | Feb → Sep 2016 | — | mads u werner | Completed | No outcome recorded |
| Phase 2 | NCT01992146 | Nov → Dec 2015 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT02137213 | Aug 2014 → Mar 2015 | constipation disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT02267304 | Oct 2013 → Aug 2016 | — | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 2 | NCT01939444 | Aug 2013 → Oct 2014 | — | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT01582347 | Mar → Nov 2012 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00984334 | Oct 2009 → Jan 2012 | chronic pain syndrome, opioid-induced constipation | S.L.A. Pharma AG | Completed | No outcome recorded |
| Phase 2 | NCT00678145 | Mar 2008 → Aug 2018 | autonomic nervous system disorder, hypoglycemia, type 1 diabetes mellitus | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00640835 | Feb → Oct 2008 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01293058 | Mar → Jun 2007 | acute opioid poisoning | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01967641 | Nov 2005 → Jun 2011 | opiate dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00125931 | Sep 2005 → Aug 2008 | bipolar disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00142896 | Feb → Dec 2005 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00149539 | Jun 2004 → Jan 2006 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Terminated | No outcome recorded |
| Phase 2 | NCT00330343 | May 2004 → Jun 2009 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00108446 | Oct 2003 → Mar 2006 | irritable bowel syndrome | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00000331 | Dec 2002 | heroin dependence | University of Colorado, Denver | Withdrawn | No outcome recorded |
| Phase 2 | NCT00000328 | Jul → Aug 1997 | heroin dependence | University of Colorado, Denver | Withdrawn | No outcome recorded |
| Phase 2 | NCT00000298 | Aug 1995 → ? | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05011266 | Apr 2023 → Jan 2027 expected | opiate dependence | New York State Psychiatric Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02581111 | Sep 2015 → Sep 2017 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT00992576 | Jan 2010 → Nov 2011 | constipation disorder | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT03678792 | Nov 2019 → Sep 2020 | opiate dependence, substance withdrawal syndrome | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 3 | NCT03711318 | Nov 2018 → Dec 2021 | heroin dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 3 | NCT03518021 | May 2018 → Oct 2020 | acute opioid poisoning, substance abuse | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT03687268 | Jul 2017 → Nov 2019 | opioid-induced constipation | Develco Pharma Schweiz AG | Unknown | No outcome recorded |
| Phase 3 | NCT02651584 | Dec 2015 → Oct 2016 | opiate dependence | Braeburn Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02332447 | Jun 2015 → Jul 2020 | epilepsy | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT02109640 | Oct 2014 → Aug 2015 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT01918098 | Sep 2013 → Mar 2017 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01885182 | Jun 2013 → Aug 2015 | cancer | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01438567 | Sep 2011 → Feb 2014 | constipation disorder | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01427270 | Aug 2011 → Oct 2014 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01358526 | May 2011 → Oct 2012 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01112644 | Apr 2010 → Jun 2011 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01167699 | Jun 2009 → Apr 2011 | — | Mundipharma Pharmaceuticals B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01760473 | May 2009 → Dec 2014 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT00679614 | Dec 2007 → May 2011 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT00412100 | Apr 2006 → Jul 2008 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT00286052 | Dec 2002 → Aug 2004 | substance-related disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00032955 | Feb 2001 → Aug 2002 | heroin dependence, morphine dependence, substance withdrawal syndrome | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00032968 | Jan 2001 → Aug 2002 | heroin dependence, morphine dependence, substance withdrawal syndrome | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00020605 | May 2000 → ? | cancer of unknown primary site, constipation disorder | Dana-Farber Cancer Institute | Unknown | No outcome recorded |
| Phase 3 | NCT01713803 | ? → May 2017 | opiate dependence | BioDelivery Sciences International | Withdrawn | No outcome recorded |
| Phase 432 trials | ||||||
| Phase 4 | NCT06897917 | Apr → Dec 2025 overdue | opioid-induced constipation | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06666621 | Aug 2024 → Oct 2025 overdue | arthritic joint disease | Middle Tennessee Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT05876572 | Aug → Dec 2024 | acute opioid poisoning | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04303000 | Jul 2021 → Jan 2022 | acute opioid poisoning | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT04811014 | Apr 2021 → Aug 2030 expected | acute opioid poisoning, opiate dependence | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT04088266 | Jan → Dec 2020 | — | Teva Pharmaceuticals USA | Withdrawn | No outcome recorded |
| Phase 4 | NCT03179475 | Sep 2019 → Nov 2021 | chronic pain syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT03908437 | Jul 2019 → Mar 2022 | opiate dependence, poisoning | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT03608163 | Jan → Aug 2019 | hypoglycemia, type 1 diabetes mellitus | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT03740243 | Nov 2018 → Mar 2020 | substance-related disorder | Stony Brook University | Withdrawn | No outcome recorded |
| Phase 4 | NCT05301712 | Aug 2018 → Oct 2022 | stroke disorder | Samjin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03396276 | Apr 2018 → Aug 2030 expected | substance-related disorder | The University of Texas Health Science Center, Houston | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03176316 | Sep 2017 → Feb 2020 | ileus | Loyola University | Terminated | No outcome recorded |
| Phase 4 | NCT02885948 | Apr 2016 → Dec 2017 | respiratory underresponsiveness to hypoxia and hypercapnia | University College Dublin | Completed | No outcome recorded |
| Phase 4 | NCT01875848 | Dec 2013 → Jun 2015 | — | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 4 | NCT02038790 | Nov 2013 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01912573 | Sep 2013 → Sep 2014 | — | Judith Feinberg | Unknown | No outcome recorded |
| Phase 4 | NCT01675531 | Dec 2012 → Dec 2013 | cancer | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01846455 | Sep 2012 → Apr 2013 | chronic hepatitis C virus infection, liver failure | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01719757 | Jul 2012 → Oct 2013 | cancer | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02573922 | May 2012 → Dec 2014 | constipation disorder | Kuopio University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01313780 | May 2011 → Oct 2013 | cancer | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01083485 | Mar → Oct 2010 | — | Mundipharma Oy | Completed | No outcome recorded |
| Phase 4 | NCT00955162 | Aug 2009 → May 2010 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00879996 | Apr 2009 → Oct 2011 | opiate dependence | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT00901875 | Mar → Nov 2009 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00784810 | Feb 2009 → Mar 2010 | osteoarthritis | Napp Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 4 | NCT00604188 | Feb 2008 → Dec 2009 | opiate dependence | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00799201 | Aug 2007 → Oct 2012 | constipation disorder | CAMC Health System | Terminated | No outcome recorded |
| Phase 4 | NCT00684073 | Jul → Dec 2007 | opiate dependence, substance abuse | Indivior Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00315341 | Apr 2006 → Aug 2010 | opiate dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00007527 | Aug 1999 → Jan 2002 | opiate dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT05360030 | May → Dec 2022 | chronic pain syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT05142267 | Mar 2022 → Jul 2026 overdue | substance-related disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| — | NCT04518618 | Sep 2020 → Mar 2021 | — | Tanta University | Completed | No outcome recorded |
| — | NCT02469077 | Aug 2015 → Sep 2019 | chronic pain syndrome | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02405988 | Apr 2015 → Feb 2016 | — | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT02856087 | Nov 2014 → Apr 2015 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02416115 | Jul → Sep 2014 | — | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT01160432 | May → Jul 2013 | opiate dependence | Kuopio University Hospital | Withdrawn | No outcome recorded |
| — | NCT01531439 | Nov 2011 → May 2015 | scoliosis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT00947284 | Jan 2010 → Jun 2012 | — | University of California, San Francisco | Terminated | No outcome recorded |
| — | NCT00958919 | Aug 2009 → Aug 2010 | chronic obstructive pulmonary disease | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT00890942 | May → Oct 2009 | poisoning | Mahidol University | Completed | No outcome recorded |
| — | NCT00679458 | Sep 2008 → Nov 2009 | — | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT00716807 | Jan 2008 → Jun 2010 | burning mouth syndrome, temporomandibular joint dysfunction syndrome | University of California, San Francisco | Terminated | No outcome recorded |
| — | NCT00486330 | May 2006 → May 2007 | HIV infectious disease | Yale University | Completed | No outcome recorded |
| — | NCT00184938 | Jan 2005 → ? | ischemic disease | Radboud University Medical Center | Suspended | No outcome recorded |
| — | NCT00134888 | Dec 2000 → Nov 2002 | opiate dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| — | NCT00134875 | Dec 2000 → Dec 2002 | substance-related disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| — | NCT00158236 | Jan 1997 → Mar 1998 | opioid abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 77 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06726200 Comparator | Feb 2026 → Jan 2029 expected | substance-related disorder | Rachel R. Luba | Recruiting | No outcome recorded |
| Phase 0 | NCT03489161 Background | Aug 2018 | opiate dependence, substance withdrawal syndrome | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 111 trials | ||||||
| Phase 1 | NCT06406400 Background | May → Jul 2024 | opiate dependence | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT06719986 Comparator | Oct → Dec 2022 | acute opioid poisoning | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT04828005 Comparator | Mar 2021 → Mar 2022 | — | Opiant Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT05363501 Comparator | Jan 2021 → Apr 2022 | acute opioid poisoning | Pocket Naloxone Corp | Completed | No outcome recorded |
| Phase 1 | NCT04447287 Background | Jun → Nov 2020 | substance-related disorder | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02045693 Comparator | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01622504 Comparator | Jun → Jul 2012 | acute opioid poisoning | Mitovie Pharma Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01596764 Comparator | May → Jul 2011 | intestinal obstruction | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT01275599 Background | Jan → Apr 2011 | chronic hepatitis C virus infection, opiate dependence | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT00886002 Background | Nov 2004 → Jan 2005 | — | Janssen-Cilag A.G., Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00714558 Background | Apr → May 2003 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04851301 Comparator | Nov 2021 → Dec 2025 overdue | temporomandibular joint disorder | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04818086 Comparator | May 2021 → Apr 2023 | substance-related disorder | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT03580902 Background | Jan 2019 → Nov 2021 | opiate dependence | CBT4CBT, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01188421 Comparator | Oct 2010 → Jun 2015 | opiate dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06251609 Comparator | Nov 2026 → Dec 2028 expected | acute opioid poisoning, cardiac arrest | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07459166 Comparator | May → Jul 2026 overdue | acute opioid poisoning | Clear Scientific, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT03066739 Comparator | Feb 2023 → Dec 2024 | — | University of California, Irvine | Terminated | No outcome recorded |
| Phase 2 | NCT03744663 Comparator | Jun → Dec 2022 | substance-related disorder | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT05027919 Background | Dec 2021 → Nov 2026 expected | opiate dependence, substance withdrawal syndrome | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 2 | NCT03897998 Comparator | Nov 2021 → Dec 2025 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT03430180 Comparator | Feb 2018 → Aug 2019 | pathological gambling | Finnish Institute for Health and Welfare | Unknown | No outcome recorded |
| Phase 2 | NCT03223896 Comparator | Feb → Jun 2017 | pathological gambling, substance-related disorder | Finnish Institute for Health and Welfare | Completed | No outcome recorded |
| Phase 2 | NCT02307305 Background | Aug 2014 → Dec 2016 | neuropathy, painful | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02044094 Background | Nov 2013 → Jul 2014 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01666119 Background | Aug 2012 → Jan 2013 | opiate dependence | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT01197261 Comparator | Sep 2010 → Mar 2013 | interstitial cystitis | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2 | NCT00944697 Comparator | Jul 2009 → Mar 2010 | diabetic polyneuropathy | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2 | NCT01218984 Background | Mar 2002 → May 2003 | opiate dependence | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00000236 Background | — | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT04893525 Comparator | Jul 2021 → Dec 2026 expected | substance-related disorder | University of British Columbia | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02321397 Comparator | Nov 2014 → Mar 2016 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2/3 | NCT01567670 Comparator | Aug 2011 → Jun 2012 | binge eating disorder | Lightlake Sinclair Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT01071057 Comparator | Dec 2010 → Apr 2013 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06408714 Comparator | Aug → Dec 2024 | acute opioid poisoning | University of New Mexico | Withdrawn | No outcome recorded |
| Phase 3 | NCT06089707 Background | Jan 2024 → Jan 2026 overdue | opiate dependence | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT03616236 Background | Jul 2022 → Aug 2026 | substance-related disorder | Friends Research Institute, Inc. | Suspended | No outcome recorded |
| Phase 3 | NCT02811783 Comparator | Jan 2017 → Sep 2022 | Sezary syndrome, mycosis fungoides | Elorac, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01717963 Comparator | Oct 2012 → Aug 2016 | opiate dependence | University of Oslo | Completed | No outcome recorded |
| Phase 3 | NCT01439100 Comparator | Oct 2011 → Aug 2013 | Parkinson disease | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01014559 Comparator | Feb 2010 → Jun 2011 | constipation disorder | Mundipharma SAS | Terminated | No outcome recorded |
| Phase 3 | NCT01167127 Comparator | Jun 2009 → Apr 2011 | — | Mundipharma Pharmaceuticals B.V. | Completed | No outcome recorded |
| Phase 3 | NCT00710385 Comparator | Sep 2007 → Aug 2008 | substance-related disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 3 | NCT01971632 Comparator | Jan 2005 → May 2006 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07439549 Background | Apr → Sep 2026 expected | opiate dependence | Pouya Azar | Recruiting | No outcome recorded |
| Phase 4 | NCT05808881 Comparator | Jun 2023 → May 2024 | acute opioid poisoning | Purdue Pharma LP | Withdrawn | No outcome recorded |
| Phase 4 | NCT05594121 Comparator | Dec 2022 → Dec 2023 | opiate dependence | Royal Victoria Hospital, Canada | Unknown | No outcome recorded |
| Phase 4 | NCT04771689 Comparator | Jul 2022 → Dec 2025 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04375033 Background | Nov 2020 → Sep 2028 expected | opiate dependence | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT04234516 Comparator | Jan 2020 → Jun 2021 | opiate dependence | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT02939248 Comparator | Oct 2016 → Dec 2018 | intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT02516059 Comparator | Sep 2015 → Feb 2017 | urinary bladder cancer | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT02032927 Comparator | Jun 2013 → Jun 2015 | chronic pain syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Withdrawn | No outcome recorded |
| Phase 4 | NCT01838616 Comparator | Apr 2013 → Jan 2014 | neuropathy, painful | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01559454 Background | Feb 2012 → May 2014 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT01816581 Comparator | Jul 2011 → May 2012 | postoperative ventricular dysfunction | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01374763 Comparator | Jul → Dec 2011 | — | Kati Järvelä | Completed | No outcome recorded |
| Phase 4 | NCT01191645 Comparator | Oct → Nov 2010 | dyskinesia of esophagus | Region Örebro County | Completed | No outcome recorded |
| Phase 4 | NCT01109511 Comparator | Mar 2010 → Jun 2011 | opioid-induced constipation | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00921765 Comparator | Dec 2009 → Dec 2017 | — | Ullevaal University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01015066 Comparator | Nov 2009 → Jun 2014 | opiate dependence | State University of New York at Buffalo | Withdrawn | No outcome recorded |
| Phase 4 | NCT00605033 Comparator | Mar 2008 → Apr 2009 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT06390046 Background | Apr → Dec 2024 | — | Jagiellonian University | Completed | No outcome recorded |
| — | NCT04673812 Comparator | Dec 2020 → Mar 2021 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| — | NCT03586466 Background | Dec 2018 → Sep 2020 | opiate dependence | MedicaSafe, Inc. | Unknown | No outcome recorded |
| — | NCT03372486 Comparator | Dec 2017 → Apr 2018 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT02922959 Background | Feb 2017 → Jul 2019 | drug dependence, substance abuse | University of Cincinnati | Completed | No outcome recorded |
| — | NCT03230474 Comparator | May 2016 → Feb 2017 | — | Assiut University | Completed | No outcome recorded |
| — | NCT03014843 Comparator | Oct 2013 → Jan 2014 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01851486 Comparator | Jan 2013 → Sep 2016 | — | Rambam Health Care Campus | Withdrawn | No outcome recorded |
| — | NCT01550341 Comparator | Feb 2012 → Nov 2015 | AIDS, opiate dependence | Yale University | Completed | No outcome recorded |
| — | NCT01549652 Background | Apr 2011 → Apr 2015 | drug dependence, substance withdrawal syndrome | Stanford University | Completed | No outcome recorded |
| — | NCT01105871 Comparator | Aug 2010 → Jun 2014 | — | University of Washington | Unknown | No outcome recorded |
| — | NCT00458419 Comparator | Sep 2005 → May 2007 | chronic obstructive pulmonary disease | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT00249574 Background | Jun 2003 → Mar 2004 | hepatitis C virus infection, heroin dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S. tevapharm.com ↗ |
Evidence & citations 50 cited values
Every value below carries the sentence it was read from. 227 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | naloxone | “The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10...” NCT02880475 ↗220“The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy,...” NCT00000331 ↗ “The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of...” NCT00733720 ↗ “A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment.” NCT02038790 ↗ “determine the ability of intranasal and intravenous naloxone and intravenous nalmefene to reverse opioid (fentanyl and sufentanil)- induced respiratory depression” NCT05338632 ↗ “The purpose of this study is to compare the clinical efficacy of the buprenorphine/naloxone combination tablet to methadone for opioid maintenance treatment.” NCT00000328 ↗ “To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.” NCT02070718 ↗ “oral Targin (a combination of oxycodone-hydrochloride and the opioid antagonist naloxone hydrochloride-dihydrate) or patient-controlled IV morphine” PMID 24375220 ↗ Dec 2013 “Targinact is a combination of prolonged release opioid analgesic (oxycodone hydrochloride) and naloxone hydrochloride (an opioid receptor blocker).” NCT02109640 ↗ “BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.” NCT01666119 ↗ “Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.” NCT01582347 ↗ “a daily sublingual (SL) combination of buprenorphine hydrochloride and naloxone hydrochloride in the treatment of opioid use disorder.” PMID 29799968 ↗ Jun 2018 “Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening.” NCT00829777 ↗ “buprenorphine/naloxone (BUP/NLX) therapy sequentially underwent baseline and steady-state pharmacokinetic evaluation” PMID 19726139 ↗ Sep 2009 “The naloxone is included with buprenorphine as a deterrent to prevent intravenous injection of the drug for abuse.” NCT03489161 ↗ “Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.” NCT01760473 ↗ “Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given.” NCT01068847 ↗ “naloxone (naloxone hydrochloride) + oxycodone (oxycodone hydrochloride)” NCT06390046 ↗ “Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given” NCT00733239 ↗ “Naloxone hydrochloride is a pure opioid competitive antagonist.” NCT04673812 ↗ “single naloxone 5 mg autoinjector intramuscular (IM) injection” NCT05264493 ↗ “Daily Sublingual Buprenorphine With Naloxone (Suboxone®)” NCT05594121 ↗ “Talwin (a combination of pentazocine and naloxone)” NCT00125931 ↗ “Contains Buprenorphine Hydrochloride and Naloxone.” NCT00604188 ↗ “Naloxone (NAL) .4 mg. Administered intravenously” NCT00710385 ↗ “8mg of buprenorphine/2mg of naloxone” NCT03396276 ↗ “sublingual buprenorphine/naloxone” NCT03744663 ↗ “Targin (Oxycodone/Naloxone)” NCT01675531 ↗ |
| Known as | 6β-Naltrexol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00829777 ↗ |
| Known as | AIKO-150 | “A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.” NCT00829777 ↗ |
| Known as | Anhydrous naloxone hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Dbl naloxone | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | EN-15304 | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Evzio | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Evzio (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Kloxxado | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxon B Braun | “Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be...” NCT02598856 ↗ |
| Known as | Naloxona | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone = Narcan | “Naloxone = Narcan” NCT01105871 ↗1“Naloxone: Narcan” NCT01068847 ↗ |
| Known as | Naloxone B Braun 0,4 mg/ml | “Naloxone B Braun 0,4 mg/ml” NCT02405988 ↗ |
| Known as | Naloxone B. Braun | “IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position” NCT01939444 ↗ |
| Known as | Naloxone chlorhydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone HCl | “Treatment C: Naloxone HCl Intravenous (IV) Injection” NCT03827642 ↗1“Naloxone HCl intranasal” NCT06719986 ↗ |
| Known as | Naloxone Hydrichloride | “A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes.” NCT03419858 ↗ |
| Known as | Naloxone hydrochloride | “A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes.” NCT04034004 ↗11“Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM” NCT03518021 ↗ “Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)” NCT01596764 ↗ “Naloxone hydrochloride is currently only recommended and licensed for intravenous, intramuscular and subcutaneous administration.” NCT01622504 ↗ “Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril)” NCT03430180 ↗ “naloxone (naloxone hydrochloride) + oxycodone (oxycodone hydrochloride)” NCT06390046 ↗ “Naloxone Hydrochloride 0.4 MG/ML” NCT07439549 ↗ “Naloxone hydrochloride 5.0mg/5ml” NCT05301712 ↗ “Naloxone hydrochloride 20mg/ml” NCT03223896 ↗ |
| Known as | Naloxone hydrochloride (autoinjector) | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride component of bunavail | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride component of cassipa | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride component of suboxone | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride component of talwin nx | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride component of targiniq | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride component of zubsolv | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | naloxone hydrochloride dihydrate | “Oxycodone hydrochloride and naloxone hydrochloride dihydrate combined oral prolonged release tablets (OXN PR), is the investigational product to be used in this study.” NCT01439100 ↗ |
| Known as | Naloxone hydrochloride dihydrate component of bunavail | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone hydrochloride dihydrate component of cassipa | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxone Hydrochloride Injection | “Drug: Naloxone Hydrochloride Injection” NCT05808881 ↗ |
| Known as | Naloxoni hydrochloridum anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Naloxoni hydrochloridum dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Narcan | “This study evaluated effectiveness of 4 mg intranasal naloxone (Narcan; Adapt Pharma Inc., USA) in reversing moderate respiratory depression induced by fentanyl and sufentanil...” PMID 41642634 ↗ Feb 20261“naloxone administration (Narcan, 4 mg)” NCT06089707 ↗ |
| Known as | Narcan (naloxone) | “Narcan® (naloxone)” NCT01218984 ↗ |
| Known as | Narcan neonatal | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Narcanti | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Narconil | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | NIH 7890 | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | NLX | “During testing, the following dose combinations of vaped cannabis (V-CB) and intranasal naloxone (IN-NLX) were tested:” PMID 40839512 ↗ Aug 2025 |
| Known as | NSC-70413 | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | NSC-757109 | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Nyxoid | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Prenoxad | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Rextovy | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Rezenopy | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Rivive | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Known as | Zimhi | ChEMBL registry synonym — accepted as the source's own label CHEMBL80 ↗ |
| Action | Inhibit | “opioid receptor antagonist” NCT00184938 ↗ |
| Modality | Small molecule | — CHEMBL80 ↗ |
| Route | Oral | “Patients receive oral naloxone twice daily.” NCT00020605 ↗ |